Systemic therapy for cervical cancer with potentially regulatable oncolytic adenovirusesAnti-tumor activity of a miR-199-dependent oncolytic adenovirusSPECT/CT imaging of hNIS-expression after intravenous delivery of an oncolytic adenovirus and 131ITissue-specific promoters active in CD44+CD24-/low breast cancer cells31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part oneChapter eight--Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans.Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapyA recombinant adenovirus type 35 fiber knob protein sensitizes lymphoma cells to rituximab therapyBlockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity.Oncolytic adenoviruses kill breast cancer initiating CD44+CD24-/low cells.Systemic adenoviral gene delivery to orthotopic murine breast tumors with ablation of coagulation factors, thrombocytes and Kupffer cells.Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models.Calcium gluconate in phosphate buffered saline increases gene delivery with adenovirus type 5.Defects in innate immunity render breast cancer initiating cells permissive to oncolytic adenovirus.Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data.Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity.Causes of death in patients with extranodal cancer of unknown primary: searching for the primary site.Other cancers in lung cancer families are overwhelmingly smoking-related cancers.Familial Associations of Colorectal Cancer with Other Cancers.Optimized mouse model for the imaging of tumor metastasis upon experimental therapy.Adenoviruses with an αvβ integrin targeting moiety in the fiber shaft or the HI-loop increase tumor specificity without compromising antitumor efficacy in magnetic resonance imaging of colorectal cancer metastasesOncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients.Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.Oncolytic viruses for induction of anti-tumor immunity.Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans.Oncolytic immunotherapy: where are we clinically?Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma.Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor.Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.MicroRNA-mediated suppression of oncolytic adenovirus replication in human liverComparison of survival of patients with metastases from known versus unknown primaries: survival in metastatic cancer.Adenoviruses in oncology: a viable option?Mutation of the fiber shaft heparan sulphate binding site of a 5/3 chimeric adenovirus reduces liver tropism.Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14.Generation of a conditionally replicating adenovirus based on targeted destruction of E1A mRNA by a cell type-specific MicroRNA.Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents (review).Conditionally replicative adenoviruses for ovarian cancer therapy.A new generation of serotype chimeric infectivity-enhanced conditionally replicative adenovirals: the safety profile of ad5/3-Δ24 in advance of a phase I clinical trial in ovarian cancer patients.Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus.Induction of interferon pathways mediates in vivo resistance to oncolytic adenovirus.
P50
Q21144267-E4741303-6D94-4324-A8E5-680A13FB6CF0Q27307206-6E6D3CBC-F4D2-496E-A612-F08E236AF2C7Q27307734-C3FE6620-3F86-41FF-8E93-C33422E3280FQ28287391-DE8D2422-0392-44FB-A160-93D03CBBCB48Q28553703-980F6EE8-4AB7-4784-9462-83DFBAFBCF19Q30571240-14D072D8-9248-4B16-9596-D5E47D671561Q30899557-A3F3DA71-8F90-4066-8639-F14A0A4C5883Q30959165-BF8A7B96-38A9-473D-80B9-031B59570BB3Q33186765-24BA1A7F-C997-4B51-8BCB-0CAD417239A0Q33298585-739CFC48-24F4-4530-94A4-771C00BC7F68Q33385742-AF33B68B-4D06-410C-8E58-7E5566F61271Q33558337-C0F4426B-EFB9-45F6-9561-EBE454601675Q33711997-B3CCD82C-A66C-404D-A640-5B8CB1757FBCQ33747762-F22103C0-D289-4B42-967E-29D14367573AQ33761673-260AD9F8-AA69-44F1-9C88-38D10440930FQ33802690-01B40A46-1F17-4462-999F-D298D4445343Q33830156-3854CEE7-E1E3-4089-8D4A-8D1F4F535FA4Q33841316-6059108B-A4CC-4429-AF2A-91FB67C8272BQ33899487-3AB9AC3E-29AD-4051-832B-04683E8FBBB7Q34071624-20C5684A-B562-4642-8CB4-00BDB8C78D50Q34114153-534F06DD-C1C8-47A8-8898-F715C0B873FBQ34116267-4F4A0212-EBF6-4A8F-B647-8682BCA2929AQ34183436-90802A6C-B6FF-4C8C-963F-90E2F41CC85AQ34198912-93E7990B-EAEB-4564-927D-93938D0286D1Q34394688-1B563804-AB76-452D-AEB1-3B282417315DQ34405325-C938A937-36C0-4806-9E76-1464F76E2568Q34426949-A8704E7C-EAAB-4D5E-8455-B795AC3E644FQ34476462-817FA1A1-DE5F-4FB3-B6B9-1E4A819BDDD2Q34496969-12A2E9A8-4602-48AD-8EA5-43C0305AFD34Q34563212-F648CA57-0271-4C1F-A4EB-C441ADE5ECE8Q34565458-FA9F0B35-7410-4E4E-B9FD-4EE72942490DQ34621411-EEB6D4BD-65A5-4863-9774-B21DA0D46798Q34667746-50134D48-350B-4770-9969-2D43BB1706D3Q34781681-56E0631A-E9C7-402C-8E6A-5A6794E6A1BAQ34830129-C26F0497-2065-4AFE-B7E4-510405BDAE14Q34995657-9BA14BA2-07B4-4063-88F1-A3CE03CB408BQ35023181-49F7C64D-3F15-4F25-9D33-FFECC5E1DD9FQ35101968-92FE3B85-0A42-4A2C-8459-F719ECC448B2Q35238258-B0F43613-DC0B-422E-9EB3-E8B990DF5377Q35285768-014A9626-5130-4940-A804-207362821038
P50
description
Fins arts
@nl
dokter asal Finlandia
@id
finnischer Arzt und Onkologe
@de
hulumtues
@sq
investigador
@es
researcher
@en
طبيب فنلندي
@ar
name
Akseli Hemminki
@ast
Akseli Hemminki
@ca
Akseli Hemminki
@en
Akseli Hemminki
@es
Akseli Hemminki
@fi
Akseli Hemminki
@fr
Akseli Hemminki
@ga
Akseli Hemminki
@nl
Akseli Hemminki
@sl
Akseli Hemminki
@sq
type
label
Akseli Hemminki
@ast
Akseli Hemminki
@ca
Akseli Hemminki
@en
Akseli Hemminki
@es
Akseli Hemminki
@fi
Akseli Hemminki
@fr
Akseli Hemminki
@ga
Akseli Hemminki
@nl
Akseli Hemminki
@sl
Akseli Hemminki
@sq
altLabel
A Hemminki
@en
A. Hemminki
@en
Hemminki A
@en
Hemminki A.
@en
Hemminki
@en
Hemminki-A
@en
prefLabel
Akseli Hemminki
@ast
Akseli Hemminki
@ca
Akseli Hemminki
@en
Akseli Hemminki
@es
Akseli Hemminki
@fi
Akseli Hemminki
@fr
Akseli Hemminki
@ga
Akseli Hemminki
@nl
Akseli Hemminki
@sl
Akseli Hemminki
@sq
P106
P21
P27
P31
P496
0000-0001-7103-8530
P569
1973-07-27T00:00:00Z